PDS Biotechnology Q2 EPS $(0.23) Beats $(0.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology (NASDAQ:PDSB) reported a Q2 EPS loss of $(0.23), beating the analyst consensus estimate of $(0.34) by 32.35%. This represents a 37.84% improvement over the $(0.37) loss per share from the same period last year.
August 13, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotechnology (NASDAQ:PDSB) reported a Q2 EPS loss of $(0.23), beating the analyst consensus estimate of $(0.34) by 32.35%. This represents a 37.84% improvement over the $(0.37) loss per share from the same period last year.
The better-than-expected EPS results and significant year-over-year improvement are likely to positively impact PDSB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100